Next Gen Microbiome and Probiotics- Virtual Conference (Time Zone- Eastern Standard Time (EST))

Online Registration

Welcome note from MarketsandMarkets

Opening Remarks from the Chairman

Julius Goepp, CEO, Evimero

MICROBIOME AS A SCIENCE AND ITS CLINICAL APPLICATIONS- SKIN, GUT & WOMEN’S HEALTH

The development of ammonia oxidizing bacteria to treat pruritus associated with atopic dermatitis in a 576 patient Phase 2b trial

Todd Krueger, President & CEO, AOBiome

Innovative microbiome product development: building an integrated regulatory and market access strategy

Clara Desvignes, Senior Regulatory Scientist, Voisin Consulting Life Sciences

Designing Beauty from Within: Optimizing Clinical Study Protocols in Probiotic Research

Kathy Musa-Veloso, Senior Director: Nutrition, Health Claims, and Clinical Trials, Intertek

Therapeutic advances in creating Next Generation skincare products using Live Probiotic Technology

Maya Ivanjesku, Chief Scientific Officer, M2B Pharma

V-Bella Homeopathic Boric Acid and Probiotic blend vaginal suppositories

Allison Krebs-Bensch, CEO , US Pharmaceutical Corporation

One-to-One Networking Meetings | Networking break- virtual networking lounge

OVERCOMING MICROBIOME RESEARCH AND PROBIOTICS PRODUCT DEVELOPMENT CHALLENGES

Fireside chat: Imagine living in a world where Illness is optional - Understanding human biology to prevent and intercept Chronic diseases

Naveen Jain, Founder & CEO, Viome

Linking the microbiome and metabolome to host health and disease

Tal Korem, Assistant Professor, Columbia University, Irving Medical Center

Advancements in Probiotic Delivery Systems: MAKTrek-3D

Bruce Topping, Director of Product Development, HempFusion, Inc.

LBPs: When choosing a CDMO for your live biotherapeutics, what are the important aspects that a company should consider? For example:

Julie Schwedock, Associate Director, Microbial Development Team, Takeda Pharmaceuticals

Harnessing the skin biome: A new paradigm for health

Nicole M. Scott, CEO and Founder, Cybele Microbiome

Closing remarks from the chairperson | End of Day 1

One-to-One Networking Meetings | Networking break- virtual networking lounge - End of day 1

Online Registration

Welcome note from MarketsandMarkets

Opening Remarks from the Chairman

Yug Varma, CEO, Phi Therapeutics

MICROBIOME DISCOVERIES

Personalised Beauty Prescription:Personnalisation in beauty is on the rise for creating the right fit for every person

Petronille Houdart, Skincare Director, Sequential Skin

Encounter with the unknown - How the alternative method “Fluorescence In Situ Hybridization (FISH)” can accelerate microbiome research and improve quality control of LBP production

Jiri Snaidr, Founder & CEO, Vermicon AG

Modulating Microbiome Signaling Pathways: A Drug Discovery Platform

Julius Goepp, CEO, Evimero

Bacteriophage Endolysins as a novel approach to modulate the skin microbiome

Skyler Stein, President, Gladskin

The Oral Microbiome, Mucosal Inflammation and its Rehabilitation

Emily Stein, CEO, Primal Health Inc.

More than gut feeling, opportunities for microbiome based solutions

Jean-Philippe Kunz, Co-Founder, Gnubiotics Sciences

Precise Microbiome Editing: A Pathway to Mechanistic and Clinical Insights Into the Microbiome

Yug Varma, CEO, Phi Therapeutics

Microbiome Science is Unlocking Important Value for Animal Health

Scott Carter, VP, Microbials Business, Phibro Animal Health Corporation

R&D TO COMMERCIALIZATION- EFFECTIVELY TRANSLATING RESEARCH INTO COMMERCIALIZATION

Panel discussion - Tackling the hurdle of going from science to commercialization without the need of license of medical devices

Closing remarks from the chairperson

One-to-One Networking Meetings | Networking break- virtual networking lounge- End of Conference